Guidance for Catalyst Pharmaceutical Partners Inc. (CPRX)
| Period | Range | Estimate | Revenue Range | Revenue Estimate | Target | Details |
|---|---|---|---|---|---|---|
| 2026 | N/A | N/A | $615.00M – 645.00M | $615.60M | = Maintained | Details |
| 2025 | N/A | N/A | $565.00M – 585.00M | $562.10M | = Maintained | Details |
| 2025 | N/A | N/A | $545.00M – 565.00M | $560.70M | = Maintained | Details |
| 2025 | N/A | N/A | $545.00M – 565.00M | $557.20M | = Maintained | Details |
| 2025 | N/A | N/A | $545.00M – 565.00M | $558.00M | = Maintained | Details |
| 2024 | N/A | N/A | $475.00M – 485.00M | $473.70M | = Maintained | Details |
| 2024 | N/A | N/A | $455.00M – 475.00M | $462.40M | = Maintained | Details |
| 2024 | N/A | N/A | $455.00M – 475.00M | $460.50M | = Maintained | Details |
| 2023 | N/A | N/A | $390.00M – 395.00M | $389.10M | = Maintained | Details |
| 2023 | N/A | N/A | $195.00M – 205.00M | $165.80M | = Maintained | Details |
| 2023 | N/A | N/A | $375.00M – 385.00M | $382.70M | = Maintained | Details |
| Q3 2023 | N/A | N/A | $380.00M – 390.00M | N/A | = Maintained | Details |
| 2022 | N/A | N/A | $205.00M – 210.00M | $205.00M | = Maintained | Details |
| 2020 | N/A | N/A | $135.00M – 155.00M | $140.00M | = Maintained | Details |
| 2020 | N/A | N/A | $135.00M – 155.00M | $166.60M |  Lowered |
Details |
| 2019 | N/A | N/A | $100.00M | $111.00M | Lowered |
Details |
| Q2 2018 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q1 2018 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q4 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q3 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q2 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q1 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
